Search Result

Pathways Recommended:	JAK/STAT Signaling

Results for "

JAK Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (461) Ack1 (1) Acyltransferase (1) Akt (32) Aldose Reductase (1) AMPK (8) Amyloid-β (4) Anaplastic lymphoma kinase (ALK) (3) Antibiotic (5) Apoptosis (145) Arginase (1) Atg8/LC3 (3) Aurora Kinase (9) Autophagy (42) Bacterial (17) Bcl-2 Family (7) Bcr-Abl (7) Biochemical Assay Reagents (1) BMX Kinase (1) Btk (11) c-Kit (1) c-Myc (5) Cadherin (1) Calcium Channel (1) Cannabinoid Receptor (1) Caspase (15) Cathepsin (1) CDK (10) COX (4) CXCR (1) Cytochrome P450 (4) Deubiquitinase (5) Discoidin Domain Receptor (1) DNA/RNA Synthesis (10) Dopamine Receptor (1) Drug Derivative (2) Drug Intermediate (2) Drug Metabolite (3) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) EGFR (15) Endogenous Metabolite (10) Epigenetic Reader Domain (2) ERK (6) FAK (1) Ferroptosis (9) FGFR (3) Flavivirus (1) FLT3 (33) Fluorescent Dye (1) FOXO (1) Fungal (8) G Protein-coupled Receptor Kinase (GRK) (1) Glucocorticoid Receptor (1) GLUT (3) Glutathione Peroxidase (1) GSK-3 (7) HBV (1) HDAC (7) HIF/HIF Prolyl-Hydroxylase (3) HIV (3) HSP (1) IAP (3) IFNAR (11) IGF-1R (1) IKK (8) Influenza Virus (4) Insulin Receptor (1) Interleukin Related (40) IRAK (1) Isotope-Labeled Compounds (20) Itk (2) JNK (12) Keap1-Nrf2 (6) Ligands for Target Protein for PROTAC (1) LRRK2 (1) MAP4K (1) MDM-2/p53 (1) MEK (4) MetAP (1) MHC (1) MicroRNA (2) Microtubule/Tubulin (2) Mitophagy (9) Mitosis (2) Monoamine Oxidase (2) mTOR (8) Na+/K+ ATPase (2) nAChR (2) NADPH Oxidase (1) Necroptosis (1) Neurokinin Receptor (1) NF-κB (22) NO Synthase (6) Orthopoxvirus (1) Oxidative Phosphorylation (1) p38 MAPK (17) p62 (3) Parasite (3) PARP (3) PD-1/PD-L1 (1) PDGFR (1) PERK (1) PGE synthase (1) Phosphatase (3) PI3K (29) PKC (2) Polo-like Kinase (PLK) (3) PPAR (1) Prostaglandin Receptor (1) PROTACs (7) Protease Activated Receptor (PAR) (1) Proteasome (1) Pyroptosis (1) Pyruvate Kinase (2) Raf (1) Ras (3) Reactive Oxygen Species (ROS) (16) Reference Standards (51) RET (5) RIP kinase (2) ROCK (1) ROS Kinase (1) SGLT (3) Sirtuin (11) SOD (2) Src (5) STAT (141) STING (1) Survivin (1) Syk (11) TAM Receptor (1) TGF-beta/Smad (5) TGF-β Receptor (4) TNF Receptor (13) Toll-like Receptor (TLR) (1) Trk Receptor (1) TRP Channel (1) Tyrosinase (2) VEGFR (7) Virus Protease (2) Wnt (3) YB-1 (1) β-catenin (2)
By Research Areas:	Cancer (323) Cardiovascular Disease (26) Endocrinology (2) Infection (29) Inflammation/Immunology (245) Metabolic Disease (16) Neurological Disease (30)
Click Chemistry:	Alkynes (5)
Oligonucleotides:	Antisense Oligonucleotides (2)

533

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10961

Momelotinib 15+ Cited Publications CYT387	JAK Autophagy Apoptosis	Cancer
Momelotinib (CYT387) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.

HY-14435

Pyridone 6 10+ Cited Publications	JAK	Cancer
Pyridone 6 is a *pan-JAK* inhibitor, which potently inhibits the JAK kinase family, with IC₅₀s of 1 nM for *JAK2* and TYK2, 5 nM for *JAK3, and 15 nM for JAK1*, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.

HY-109053

Delgocitinib 2 Publications Verification JTE-052	JAK	Inflammation/Immunology
Delgocitinib (JTE-052) is a specific *JAK* inhibitor with IC₅₀s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-15315A

Baricitinib phosphate 70+ Cited Publications LY3009104 phosphate; INCB028050 phosphate	JAK	Inflammation/Immunology
Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable *JAK1/JAK2* inhibitor with IC₅₀ of 5.9 nM and 5.7 nM, respectively.

HY-112724

Ivarmacitinib SHR0302	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly *JAK1. The selectivity of Ivarmacitinib for JAK1* is >10-fold for *JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits* *JAK1-STAT3* phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-13577

Oclacitinib 4 Publications Verification PF-03394197	JAK	Inflammation/Immunology
Oclacitinib is a novel *JAK* inhibitor. Oclacitinib is most potent at inhibiting *JAK1* (IC₅₀=10 nM).

HY-130247

Flonoltinib 1 Publications Verification JAK2/FLT3-IN-1	JAK FLT3 Apoptosis	Cancer
Flonoltinib is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity .

HY-15480

NSC 42834 3 Publications Verification JAK2 Inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2, inhibits* Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

HY-15508

JANEX-1 4 Publications Verification WHI-P131; JAK3 Inhibitor I	JAK	Cancer
JANEX-1 (WHI-P131) is a potent and specific *JAK3* inhibitor (estimated K_i=2.3 μM). JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC₅₀ of 78 μM), does not inhibit JAK1 and JAK2.

HY-12469

Decernotinib 4 Publications Verification VX-509; VRT-831509	JAK	Inflammation/Immunology
Decernotinib is a potent, orally active *JAK3* inhibitor, with K_is of 2.5, 11, 13 and 11 nM for *JAK3, JAK1, JAK*2, and TYK2, respectively.

HY-101976

JAK3-IN-6	JAK	Inflammation/Immunology
JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC₅₀ of 0.15 nM.

HY-10962

Momelotinib sulfate 15+ Cited Publications CYT387 sulfate salt	JAK Autophagy Apoptosis	Cancer
Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC₅₀=155 nM).

HY-169326S

JAK2-IN-11	Isotope-Labeled Compounds JAK	Cancer
JAK2-IN-11 (Example 6) is a *JAK2* kinase inhibitor with IC₅₀ ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .

HY-175684

JAK2-IN-14	JAK STAT Apoptosis	Cancer
JAK2-IN-14 is an orally active *JAK2* inhibitor with an IC₅₀ of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over *JAK1, JAK3, and TYK2, respectively. JAK2-IN-14 inhibits* STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs) .

HY-137756

JAK2-IN-6 1 Publications Verification	JAK	Cancer
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective *JAK2* inhibitor with an IC₅₀ of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells .

HY-19544

JAK3-IN-1	JAK	Cancer
JAK3-IN-1 is a potent, selective and orally active *JAK3* inhibitor with an IC₅₀ of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for *JAK3* than JAK1 (IC₅₀ of 896 nM) and JAK2 (IC₅₀ of 1050 nM) .

HY-13827

JAK-IN-1 4 Publications Verification	JAK	Inflammation/Immunology
JAK-IN-1 is a *JAK1/2/3* inhibitor with IC₅₀s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.

HY-161684

JAK2-IN-10	JAK STAT	Cancer
JAK2-IN-10 is a selective JAK2 V617F inhibitor with an IC₅₀ value of ≤10 nM . JAK2-IN-10 can be used for the research of myeloproliferative neoplasms and other related diseases .

HY-156466

QL-1200186	STAT Interleukin Related IFNAR	Inflammation/Immunology
QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC₅₀=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC₅₀=9.85 nM，TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated *JAK-STAT* signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .

HY-153568

JAK1-IN-11	JAK	Cancer
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC₅₀s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2 .

HY-116505

JAK1-IN-4	JAK	Cancer
JAK1-IN-4 is a potent and selective *JAK1* inhibitor, with IC₅₀s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC₅₀, 227 nM) .

HY-162248

JAK1/2-IN-1	JAK Interleukin Related	Inflammation/Immunology Cancer
JAK1/2-IN-1 is a potent *JAK1* and *JAK2* inhibitor with IC₅₀ values of 0.4 nM and 8.1 nM, respectively. JAK1/2-IN-1 also inhibits IL-4 and IL-13 with IC₅₀s of 136.5 nM and 19.1 nM, respectively (WO2023244775A1; Example 33a) .

HY-161015

JAK1-IN-13	JAK	Inflammation/Immunology
JAK1-IN-13 (compound 36b) is an orally active, potent and highly selective inhibitor of *JAK1* with an IC₅₀ of 0.044 nM. JAK1-IN-13 significantly decreases STAT3 phosphorylation .

HY-126141

JAK/HDAC-IN-1 1 Publications Verification	JAK HDAC Apoptosis	Cancer
JAK/HDAC-IN-1 is a potent *JAK2/HDAC* dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC₅₀s of 4 and 2 nM for JAK2 and HDAC, respectively .

HY-125019

iJak-381	JAK STAT	Inflammation/Immunology
iJak-381 is a *JAK1/2* inhibitor with anti-inflammatory activity. iJak-381 blocks IL-13 signaling and also inhibits IL-4 and IL-6 signaling pathways. iJak-381 also reduced p-STAT6 levels and inhibited the influx of inflammatory cells into the lungs of mice. iJak-381 inhibits airway hyperresponsiveness (AHR) .

HY-153440

Methyl 6-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate	JAK	Cancer
JAK-IN-25 (compound 19) is a potent *JAK* inhibitor with IC₅₀s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC₅₀ of 28 nM. JAK-IN-25 has the potential for cancer research .

HY-13961

GLPG0634 analog	JAK	Cancer
GLPG0634 analog (Compoun 176) is a broad spectrum *JAK* inhibitor with IC₅₀ values of <100 nM against JAK1, JAK2 and JAK3 .

HY-143444

JAK-IN-20	JAK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
JAK-IN-20 is a potent, pan and orally active *JAK* inhibitor with an IC₅₀s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo .

HY-100849

JAK 3i	JAK	Inflammation/Immunology
JAK3i is a highly selective *JAK3* inhibitor (IC₅₀: 0.43 nM). JAK3i forms a covalent bond with a cysteine in JAK3, but not the closely related kinase domains in JAK1, JAK2, or TYK2. JAK3i abolishes IL-2-driven T-cell proliferation in vivo and has the potential for autoimmune disease research .

HY-119935

JAK3 covalent inhibitor-1	JAK	Inflammation/Immunology
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC₅₀ of 11 nM and shows 246-fold selectivity vs other JAKs .

HY-148060

JAK-IN-21 1 Publications Verification	JAK	Cancer
JAK-IN-21 (Example 4) is a selective and potent *JAK* inhibitor with IC₅₀s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively .

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-179428

JAK2-IN-17	JAK	Cancer
JAK2-IN-17 (compound 20) is a potent *JAK2* allosteric inhibitor. JAK2-IN-17 inhibits full-length JAK2 and JAK2 V617F with IC₅₀s of 160 and 130 nM, respectively. JAK2-IN-17 covalently modifies Lys677 in the pseudokinase domain .

HY-151285

JAK-2/3-IN-3	Apoptosis JAK	Inflammation/Immunology Cancer
JAK-2-/3-IN-3 (compound ST4j) is a potent *JAK2/3* inhibitor with IC₅₀s of 13.00 and 14.86 nM for *JAK2* and *JAK3, respectively. JAK-2-/3-IN-3 inhibits* autophosphorylation of *JAK2* and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia .

HY-144440

JAK1-IN-9	JAK	Cancer
JAK1-IN-9 (compound 23a) is a potent and selective *JAK1* inhibitor with an IC₅₀ of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more .

HY-146727

JAK3-IN-11	JAK	Inflammation/Immunology
JAK3-IN-11 (Compound 12), a potent, noncytotoxic, irreversible, orally active *JAK3* inhibitor with IC₅₀ value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T cell proliferation, is a promising tool for study autoimmune diseases .

HY-112724A

Ivarmacitinib sulfate SHR0302 sulfate	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) sulfate is a potent and orally active all members of the JAK family inhibitor, particularly *JAK1. The selectivity of Ivarmacitinib for JAK1* is >10-fold for *JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits* *JAK1-STAT3* phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-18300S

Filgotinib-d4 GLPG0634-d₄	JAK	Cancer
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-162031

MMT3-72-M2	JAK	Metabolic Disease
MMT3-72-M2 is an MMT3-72 metabolite. MMT3-72-M2 is a selective *JAK1* inhibitor. MMT3-72-M2 inhibits JAK1, JAK2, TYK2, and JAK3 with IC₅₀ values of 10.8 nM, 26.3 nM, 91.6 nM, 328.7 nM, respectlly .

HY-157121

JAK-IN-34	JAK	Inflammation/Immunology
JAK-IN-34 (compound 11n) is a potent against of JAKs with IC₅₀ values of 0.40, 0.83, 2.10, 1.95 nM target JAK1, JAK2, JAK3, TYK2, respectively. JAK-IN-34 reduces joint swelling with good safety .

HY-100759

JAK2-IN-4	JAK	Cancer
JAK2-IN-4 (compound 16h) is a selective *JAK2/JAK3* inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively .

HY-178936

JAK2-IN-15	JAK STAT	Inflammation/Immunology Cancer
JAK2-IN-15 is an orally active, potent, selective *JAK2* inhibitor (IC₅₀ = 1.17 nM). JAK2-IN-15 can inhibit the AK2-STAT signaling pathway. JAK2-IN-15 significantly improves key pathological indicators such as hematocrit and splenomegaly in an Epoetin beta (HY-114134) (rhEPO)-induced mouse model. JAK2-IN-15 can be used for the study of Polycythemia Vera (PV) .

HY-10963

Momelotinib mesylate CYT387 mesylate	JAK Autophagy	Cancer
Momelotinib mesylate (CYT387 mesylate) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.

HY-120604

BVB808 NVP_BVB808	JAK STAT	Cancer
BVB808 (NVP_BVB808) is a selective *JAK2* inhibitor with approximately 10-fold selectivity for *JAK2* over other JAK family members (such as JAK1, JAK3 or TYK2) in vitro. BVB808 inhibits the activity of *JAK2* and reduces the phosphorylation of STAT5, thereby blocking the *JAK2*-dependent cell proliferation and survival signaling pathways. BVB808 can be used in cancer research .

HY-178282

JAK1-IN-19	JAK	Inflammation/Immunology
JAK1-IN-19 (Compound 18) is a potent *JAK1* inhibitor with IC₅₀s of 0.02, 0.5, 91 and 0.2 nM against *JAK1, JAK2, JAK3* and TYK2. JAK1-IN-19 exhibits improved rat and human intrinsic clearance. JAK1-IN-19 can be used for the studies of atopic dermatitis and other autoimmune diseases .

HY-130247B

Flonoltinib monomaleate JAK2/FLT3-IN-1 monomaleate	JAK FLT3 Apoptosis	Cancer
Flonoltinib maleate is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity .

HY-174988

JAK2-IN-13	JAK STAT	Cancer
JAK2-IN-13 is a potent and orally active *JAK2* inhibitor with an IC₅₀ of 54.7 nM. JAK2-IN-13 downregulates the expressions of p-STAT3 and p-STAT5. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2-IN-13 can be used for the study of myeloproliferative neoplasms .

HY-161354

JAK3 covalent inhibitor-2	JAK Apoptosis	Inflammation/Immunology
JAK3 covalent inhibitor-2 (compound J1b) is a selective, orally potent JAK3 inhibitor (IC₅₀=7.2 nM) with low toxicity, anti-inflammatory activity and good bioavailability .

HY-156535

JAK kinase-IN-1	JAK	Inflammation/Immunology
JAK kinase-IN-1 (Example 1) is a *JAK* inhibitor. JAK kinase-IN-1 inhibits TYK2, JAK1, JAK2 and JAK3 with IC₅₀ values of 4.2 nM, 32 nM, 27 nM, 3473 nM respectively .

HY-138222

JANEX-1 hydrochloride WHI-P131 hydrochloride; JAK3 Inhibitor I hydrochloride	JAK	Cancer
JANEX-1 (WHI-P131) hydrochloride is a potent and specific *JAK3* inhibitor (K_i=2.3 μM). JANEX-1 hydrochloride shows potent *JAK3* inhibitory activity (IC₅₀=78 μM), does not inhibit *JAK1* and *JAK2* .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16561

Resveratrol Maximum Cited Publications 160 Publications Verification trans-Resveratrol; SRT501	Structural Classification Classification of Application Fields Anti-aging Vitis vinifera cv. Zalema Plants Vitaceae Infection Functional Molecules Sunscreen Research of Health Products Phenols Polyphenols Cosmetic Research Inflammation/Immunology Disease Research Fields Source Classification Cancer	DNA/RNA Synthesis IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (trans-Resveratrol; SRT501) is a CNS-penetrant natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, *JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-N0678

Icaritin 5+ Cited Publications Anhydroicaritin	Flavonols Classification of Application Fields Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Epimedium brevicornu Maxim. Berberidaceae Disease Research Fields Source Classification Cancer	JAK Autophagy Apoptosis
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[3.

HY-N0697

Crocin 15+ Cited Publications Crocin I	Neurological Disease Classification of Application Fields Anti-aging Lridaceae Plants Crocus sativus L. Functional Molecules Terpenoids Research of Health Products Diterpenoids Inflammation/Immunology Disease Research Fields Cancer Source Classification	Endogenous Metabolite JAK Apoptosis
Crocin (Crocin I) is an orally active natural product that can be isolated from the stigma of Crocus sativus. Crocin inhibits tumor cell proliferation and promotes apoptosis through *JAK* pathway. Crocin has anti-inflammatory, antioxidant and antitumor activities .

HY-N0484

Liensinine 15+ Cited Publications	Cardiovascular Disease Alkaloids Structural Classification other families Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Alkaloid Dimers Source Classification	Reactive Oxygen Species (ROS) Autophagy Apoptosis VEGFR JAK Amyloid-β p38 MAPK HIF/HIF Prolyl-Hydroxylase STAT PI3K JNK Akt
Liensinine is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine exerts anti-tumor effects through ROS-mediated inhibition of the *JAK2/STAT3* signaling pathway. Liensinine can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .

HY-113402

Gamma-glutamylcysteine 4 Publications Verification γ-Glu-Cys	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, *JAK1/STAT1*/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease .

HY-N0143

Phlorizin 10+ Cited Publications Floridzin	Structural Classification Flavonoids Classification of Application Fields Malus pumila Mill. Rosaceae Phenols Polyphenols Metabolic Disease Plants Dihydrochalcones Disease Research Fields Source Classification	Caspase JAK GLUT STAT Apoptosis Bacterial SGLT mTOR Akt NF-κB PI3K DNA/RNA Synthesis
Phlorizin (Floridzin) is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against hSGLT2, and an IC₅₀ of 0.17 μM and a K_i of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the *JAK/STAT3* and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities .

HY-N1447

Ganoderic acid A 5+ Cited Publications	Triterpenes Classification of Application Fields Terpenoids Polyporaceae Ganoderma lucidum (Leyss. Ex Fr.) Karst. Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	Apoptosis Autophagy Endogenous Metabolite
Ganoderic acid A can inhibit of the *JAK-STAT3* signaling pathway, also inhibit proliferation, viability, ROS.

HY-N2409

Delphinidin chloride 2 Publications Verification	Cardiovascular Disease Classification of Application Fields Plants Anthocyans Flavonoids Microorganisms other families Solanum melongena L. Phenols Polyphenols Solanaceae Disease Research Fields Source Classification Cancer	Apoptosis EGFR JAK STAT
Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates *JAK/STAT3* and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC₅₀: 1.3 μM), shutting down downstream signaling cascades .

HY-N7452

Coumermycin A1 25+ Cited Publications	Microorganisms Antibiotics Source Classification	JAK Bacterial Orthopoxvirus
Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.

HY-N1405

Cucurbitacin I 10+ Cited Publications Elatericin B; JSI-124; NSC-521777	Triterpenes Classification of Application Fields Terpenoids Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N2959

Brevilin A 5 Publications Verification	Centipeda minima (L.) A. Braun & Asch. Classification of Application Fields Terpenoids Sesquiterpenes Plants Compositae Disease Research Fields Source Classification Cancer	JAK STAT Apoptosis Autophagy
Brevilin A is an orally active *STAT3/JAK* inhibitor (STAT3 IC₅₀=?10.6 μM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy .

HY-113402A

Gamma-glutamylcysteine TFA 4 Publications Verification γ-Glu-Cys TFA	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Interleukin Related TNF Receptor Endogenous Metabolite AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, *JAK1/STAT1*/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease .

HY-16561R

Resveratrol (Standard) Maximum Cited Publications 160 Publications Verification trans-Resveratrol (Standard); SRT501 (Standard)	Infection Functional Molecules Classification of Application Fields Sunscreen Anti-aging Research of Health Products Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Source Classification Cancer	Reference Standards IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (Standard) is the analytical standard of Resveratrol. This product is intended for research and analytical applications. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, *JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-N0732

Jolkinolide B 1 Publications Verification	Structural Classification Euphorbia fischeriana Steud. Classification of Application Fields Terpenoids Diterpenoids Euphorbiaceae Plants Disease Research Fields Cancer	IAP Akt Caspase NF-κB TGF-beta/Smad JAK Bacterial Apoptosis
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and *JAK/STAT3* pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis .

HY-N1356

Reticuline 1 Publications Verification	Cardiovascular Disease Alkaloids Classification of Application Fields Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm. Disease Research Fields Source Classification	JAK STAT NF-κB Endogenous Metabolite
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 . Reticuline exhibits cardiovascular effects .

HY-N6069

Raspberry ketone glucoside 1 Publications Verification	Classification of Application Fields Ketones, Aldehydes, Acids Rosaceae Plants Rubus corchorifolius Linn. f. Inflammation/Immunology Disease Research Fields Source Classification	Interleukin Related JAK STAT
Raspberry ketone glucoside is a melanogenesis inhibitor. Raspberry ketone glucoside inhibits melanogenesis by activating the *IL6/JAK1/STAT3* pathway, inhibiting the transcriptional activity of MITFa, and its downstream expression levels of the TYR and TYRP1a genes. Raspberry ketone glucoside shows remarkable whitening activity on both B16F10 cells in vitro and zebrafish model in vivo .

HY-116035

Nimbolide 2 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Azadirachta indica A. Juss. Plants Meliaceae Disease Research Fields Source Classification Cancer	Wnt NF-κB CDK Apoptosis
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-N1535

Ponicidin 4 Publications Verification Rubescensine B	Structural Classification other families Classification of Application Fields Terpenoids Labiatae Diterpenoids Plants Inflammation/Immunology Disease Research Fields Butea monosperma Kuntze Source Classification	RIP kinase Apoptosis Reactive Oxygen Species (ROS) JAK STAT PI3K Akt Sirtuin Necroptosis Amyloid-β
Ponicidin (Rubescensine B) is an orally active RIPK1 inhibitor with a K_d value of 135 nM. Ponicidin inhibits the *JAK2/STAT3* pathway to induce apoptosis, activates the PI3K/Akt pathway, upregulates SIRT1 expression, alleviates oxidative stress, suppresses inflammatory responses and necroptosis, and blocks cell cycle progression. Ponicidin induces ROS production to exert antiproliferative and antiviral effects, while also improving cognitive function and reducing Aβ plaque deposition. Ponicidin can be used in studies related to hepatocellular carcinoma, Alzheimer's disease, and gastric cancer .

HY-N0818

Chikusetsusaponin Iva 2 Publications Verification Calenduloside F	Triterpenes Classification of Application Fields Terpenoids Other Diseases Amaranthaceae Plants Alternanthera philoxeroides (Mart.) Griseb. Disease Research Fields Source Classification	Keap1-Nrf2
Chikusetsusaponin IVa is an orally active protein kinase activator. Chikusetsusaponin IVa binds to YAP with a K_D value of 0.388 mM. Chikusetsusaponin IVa reduces inflammatory mediators (IL-6, IL-10, COX-2) expression, NO production, promotes ROS generation, induces Apoptosis, inhibits MAPK, TAZ, and regulates Nrf2, *JAK/STAT. Chikusetsusaponin Iva has anti-H9N2 AIV* and anti-endometrial cancer activities. Chikusetsusaponin Iva shows anti-inflammatory, hepatoprotective and osteoprotective effects .

HY-N2963

Broussonin E 2 Publications Verification	Thymelaeaceae Daphne giraldii Nitsche Phenols Polyphenols Plants Source Classification	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing *JAK2-STAT3* signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis .

HY-120692

Cyclanoline chloride	Alkaloids Structural Classification Cyclea insularis (Makino) Hatusima Plants Isoquinoline Alkaloids Menispermaceae Source Classification	JAK STAT Apoptosis
Cyclanoline chloride is an alkaloid. Cyclanoline chloride can be isolated from Fangji. Cyclanoline (chloride) inhibits the phosphorylation of *JAK2* and STAT3, and induces Apoptosis. Cyclanoline chloride suppresses tumor growth in subcutaneous bladder cancer xenograft models of nude mice. Cyclanoline chloride reverses cisplatin resistance in bladder cancer cells and enhances the efficacy of Cisplatin (HY-17394). Cyclanoline chloride can be used for research related to bladder cancer .

HY-N3011

Iridin	Structural Classification Flavonoids Iridaceae Classification of Application Fields Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Inflammation/Immunology Disease Research Fields Isoflavones Source Classification	PI3K Akt Pyruvate Kinase JAK STAT NF-κB Apoptosis Reactive Oxygen Species (ROS)
Iridin is an orally active natural isoflavone. Iridin inhibits the PI3K/AKT and PKM2 signaling pathways, and downregulates the *JAK/STAT* and NF-κB pathways. Iridin induces Fas-mediated extrinsic apoptosis, G2/M cell cycle arrest, and inhibits cell proliferation. Iridin reduces inflammation, inhibits ROS production, suppresses glycolysis, and also exhibits antioxidant and antidiabetic activities. Iridin can be used in research related to gastric cancer and acute lung injury .

HY-N3710

Dehydrocrenatidine Kumujian G; O-Methylpicrasidine I	Alkaloids Simaroubaceae Pyridine Alkaloids Plants Source Classification	JAK Apoptosis
Dehydrocrenatidine, a natural alkaloid, is a specific *JAK* inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain .

HY-N0918

Desmethoxyyangonin Demethoxyyangonin; 5,6-Dehydrokavain	other families Classification of Application Fields Other Diseases Other Phenylpropanoids Phenylpropanoids Plants Disease Research Fields Source Classification	Monoamine Oxidase JAK IKK STAT NO Synthase Cytochrome P450
Desmethoxyyangonin is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin induces CYP3A23 expression and leads to skeletal muscle relaxation .

HY-N0781

Linderalactone 2 Publications Verification	Classification of Application Fields Terpenoids Sesquiterpenes Plants Lauraceae Lindera aggregata (Sims) Kosterm. Disease Research Fields Source Classification Cancer	Apoptosis
Linderalactone is an important sesquiterpene lactone isolated from Lindera aggregata. Linderalactone inhibits cancer growth by modulating the expression of apoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lung cancer A-549 cells with an IC₅₀ of 15 µM .

HY-N2282

Zingiberen newsaponin Zingiberensis newsaponin	Cardiovascular Disease Triterpenes Classification of Application Fields Terpenoids Dioscorea Zingiberensis C.H.Wright Plants Disease Research Fields Dioscoreaceae Source Classification	Aldose Reductase JAK STAT Autophagy Apoptosis NF-κB SOD Reactive Oxygen Species (ROS)
Zingiberen Newsaponin (Zingiberensis newsaponin) is an orally active type of steroid saponin compound. Zingiberen Newsaponin exerts anti-hepatocellular carcinoma (HCC) effects by inhibiting autophagy and the *AKR1C1/JAK2/STAT3* pathway. Zingiberen Newsaponin activates oxidative stress (upregulates ROS and MDA) and mitochondrial pathways, promoting cancer cell apoptosis. Zingiberen Newsaponin alleviates cerebral ischemia-reperfusion (I/R) injury by decreasing the concentration of pro-inflammatory cytokines and inhibits NF-κB. Zingiberen Newsaponin can enhance the activity of SOD, eliminate free radicals and protect nerve cells. Zingiberen Newsaponin induces platelet aggregation .

HY-N6850

Calenduloside E 1 Publications Verification	Triterpenes other families Classification of Application Fields Terpenoids Other Diseases Aralia elata (Miq.) Seem. Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification	Apoptosis Pyroptosis AMPK Bcl-2 Family JAK STAT Calcium Channel Interleukin Related TNF Receptor SOD Reactive Oxygen Species (ROS) PPAR
Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated *JAK1-STAT3* pathways to reduce cellular inflammatory responses .

HY-N0899

Wilforine	Cardiovascular Disease Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Celastraceae Tripterygium wilfordii Hook. f. Plants Disease Research Fields Source Classification	JAK STAT Wnt β-catenin
Wilforine is an orally active *JAK-STAT* pathway inhibitor with immunomodulatory effects and the ability to inhibit osteoclast fusion. Wilforine disrupts lipid raft integrity, reprograms cholesterol and glycosphingolipid metabolic pathways, regulates NF-κB and the complement system, and modulates the expression of various interleukins. Wilforine also inhibits the Wnt11/β-catenin signaling pathway and suppresses the proliferation of fibroblast-like synoviocytes. Wilforine can serve as a quality and pharmacokinetic marker for Tripterygium glycoside tablets, and can be applied to research on related diseases such as rheumatoid arthritis, inflammatory osteolysis, and SAPHO syndrome .

HY-N0909

Notoginsenoside R2 1 Publications Verification 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Neurological Disease Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification	Apoptosis MEK ERK Reactive Oxygen Species (ROS) Caspase COX β-catenin Src MDM-2/p53 JAK STAT
Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active notoginsenoside . Notoginsenoside R2 activates P90RSK and Nrf2 via the MEK1/2-ERK1/2 pathway to inhibit 6-OHDA-induced apoptotic damage in nerve cells. Notoginsenoside R2 upregulates SOX8/β-catenin by reducing miR-27a, thereby suppressing Aβ_25-35-induced neuronal apoptosis and inflammatory responses . Notoginsenoside R2 alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src. Notoginsenoside R2 alleviates hepatic fibrosis by inducing hepatic stellate cell senescence and inhibiting the inflammatory microenvironment via *JAK/STAT3* suppression . Notoginsenoside R2 can be used in research related to Parkinson's disease, Alzheimer's disease, diabetic nephropathy and hepatic fibrosis .

HY-N0885

Telocinobufagin 1 Publications Verification Telobufotoxin; Telocinobufogenin	Structural Classification Animals Classification of Application Fields Other Diseases Disease Research Fields Steroids Source Classification	JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, *JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail* and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na ⁺/K ⁺-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .

HY-125938

Cycloartenyl ferulate 1 Publications Verification Cycloartenol ferulate; Cycloartenol ferulic acid ester	Triterpenes Monophenols other families Classification of Application Fields Terpenoids Phenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Drug Derivative Apoptosis Reactive Oxygen Species (ROS) JAK STAT
Cycloartenyl ferulate (Cycloartenol ferulate; Cycloartenol ferulic acid ester) is a derivative of γ-oryzanol (HY-B2194) with multiple biological activities including antioxidant, anti-inflammatory, and anti-tumor properties. Cycloartenyl ferulate selectively binds to IFNγR1 (binding affinity K_d = 0.5 μM) to activate the canonical *JAK1/2-STAT1* signaling pathway. Cycloartenyl ferulate inhibits paraquat (PQ)-triggered apoptosis and ROS in HK2 cells. Cycloartenyl ferulate enhances the activation and cytolytic activity of natural killer (NK) cells by upregulating the expression of NK cell activation receptors (NKG2D, NKp30, NKp44) and the release of cytotoxic molecules and cytokine IFNγ. Cycloartenyl ferulate exerts anti-cancer effects in tumor mice models. Cycloartenyl ferulate can be used for the study of cancer and allergic inflammation intervention .

HY-N0697R

Crocin (Standard) Crocin I (Standard)	Structural Classification Terpenoids Diterpenoids Lridaceae Plants Crocus sativus L. Source Classification	Reference Standards Endogenous Metabolite JAK Apoptosis
Crocin (Standard) is the analytical standard of Crocin. This product is intended for research and analytical applications. Crocin (Crocin I) is an orally active natural product that can be isolated from the stigma of Crocus sativus. Crocin inhibits tumor cell proliferation and promotes apoptosis through JAK pathway. Crocin has anti-inflammatory, antioxidant and antitumor activities .

HY-N7694

Isotoosendanin 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Melia toosendan Sieb. et Zucc. Plants Meliaceae Inflammation/Immunology Disease Research Fields Source Classification	TGF-β Receptor JAK STAT Apoptosis
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the *JAK/STAT3* signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-113402R

Gamma-glutamylcysteine (Standard) γ-Glu-Cys (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine (Standard) is the analytical standard of Gamma-glutamylcysteine. This product is intended for research and analytical applications. Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, *JAK1/STAT1*/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.

HY-N6069R

Raspberry ketone glucoside (Standard)	Structural Classification Ketones, Aldehydes, Acids Rosaceae Plants Rubus corchorifolius Linn. f. Source Classification	Reference Standards Interleukin Related JAK STAT
Raspberry ketone glucoside (Standard) is the analytical standard of Raspberry ketone glucoside (HY-N6069). Raspberry ketone glucoside is a melanogenesis inhibitor. Raspberry ketone glucoside inhibits melanogenesis by activating the *IL6/JAK1/STAT3* pathway, inhibiting the transcriptional activity of MITFa, and its downstream expression levels of the TYR and TYRP1a genes. Raspberry ketone glucoside shows remarkable whitening activity on both B16F10 cells in vitro and zebrafish model in vivo .

HY-N5014

Liensinine perchlorate 15+ Cited Publications	Alkaloids Structural Classification other families Classification of Application Fields Phenols Polyphenols Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Source Classification	Reactive Oxygen Species (ROS) Autophagy Apoptosis VEGFR JAK Amyloid-β p38 MAPK HIF/HIF Prolyl-Hydroxylase STAT PI3K JNK Akt
Liensinine perchlorate is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine perchlorate suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine perchlorate activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine perchlorate exerts anti-tumor effects through ROS-mediated inhibition of the *JAK2/STAT3* signaling pathway. Liensinine perchlorate can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .

HY-N1447R

Ganoderic acid A (Standard)	Triterpenes Structural Classification Terpenoids Polyporaceae Ganoderma lucidum (Leyss. Ex Fr.) Karst. Plants Endogenous metabolite Source Classification	Reference Standards Apoptosis Autophagy Endogenous Metabolite
Ganoderic acid A (Standard) is the analytical standard of Ganoderic acid A. This product is intended for research and analytical applications. Ganoderic acid A can inhibit of the JAK-STAT3 signaling pathway, also inhibit proliferation, viability, ROS.

HY-N0678R

Icaritin (Standard) Anhydroicaritin (Standard)	Flavonols Structural Classification Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Epimedium brevicornu Maxim. Plants Endogenous metabolite Berberidaceae Source Classification	JAK Reference Standards Autophagy Apoptosis
Icaritin (Standard) is the analytical standard of Icaritin. This product is intended for research and analytical applications. Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 μM) and primary CML cells (IC₅₀ of 13.4 μM for CML-CP and 18 μM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis [3.

HY-N10623

5-epi-Arvestonate A	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Plants Compositae Seriphidium transiliense Disease Research Fields Cancer	Tyrosinase
5-epi-Arvestonate A is a sesquiterpenoid isolated from the whole plants of Seriphidium transiliense. 5-epi-Arvestonate A promotes melanogenic production by activating the transcription of microphthalmia-associated transcription factor (MITF) and tyrosinase family genes. 5-epi-Arvestonate A inhibits the expression of IFN-γ-chemokine through the JAK/STAT signaling pathway in immortalized human keratinocyte (HaCaT) cells .

HY-N2409R

Delphinidin chloride (Standard)	Structural Classification Anthocyans Flavonoids Microorganisms other families Solanum melongena L. Phenols Polyphenols Solanaceae Plants Source Classification	Apoptosis EGFR JAK STAT Reference Standards
Delphinidin (chloride) (Standard) is the analytical standard of Delphinidin (chloride). This product is intended for research and analytical applications. Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates JAK/STAT3 and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC50: 1.3 μM), shutting down downstream signaling cascades .

HY-113402AR

Gamma-glutamylcysteine TFA (Standard) γ-Glu-Cys TFA (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Interleukin Related TNF Receptor Endogenous Metabolite Reference Standards AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine (TFA) (Standard) is the analytical standard of Gamma-glutamylcysteine (TFA). This product is intended for research and analytical applications. Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, *JAK1/STAT1*/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.

HY-N1405R

Cucurbitacin I (Standard) Elatericin B (Standard); JSI-124 (Standard); NSC-521777 (Standard)	Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Source Classification Cancer	STAT JAK Reference Standards
Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N13294

Cernuumolide J TMJ-105	Terpenoids Carpesium cernuum L. Sesquiterpenes Plants Compositae Source Classification	Apoptosis JAK STAT p38 MAPK JNK ERK
Cernuumolide J (TMJ-105) is an *JAK2/STAT3* inhibitor. Cernuumolide J induces G2/M phase arrest and apoptosis in HEL leukemia cells by downregulating the phosphorylation of *JAK2, STAT3, and Erk, and activating the phosphorylation of JNK* and p38 MAPK. Cernuumolide J inhibits HEL leukemia cell growth in a time- and concentration-dependent manner, with an IC₅₀ value of 1.79 μM. Cernuumolide J can be used for research in the field of anti-cancer therapy .

HY-N2959R

Brevilin A (Standard)	Centipeda minima (L.) A. Braun & Asch. Terpenoids Sesquiterpenes Plants Compositae Source Classification	Reference Standards JAK STAT Apoptosis Autophagy
Brevilin A (Standard) is the analytical standard of Brevilin A. This product is intended for research and analytical applications. Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC₅₀= 10.6 μM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy .

HY-N12473

25-Deacetylcucurbitacin A	Triterpenes Terpenoids Cucurbitaceae Plants Cucumis melo Linn. Source Classification	JAK
25-Deacetylcucurbitacin A is a Cucurbitane-Type triterpenoid and has the potential to be an anti-cancer agent and JAK/STAT3 signaling pathway inhibitor .

HY-N0918R

Desmethoxyyangonin (Standard) Demethoxyyangonin (Standard); 5,6-Dehydrokavain (Standard)	Structural Classification other families Other Phenylpropanoids Phenylpropanoids Plants Source Classification	Reference Standards Monoamine Oxidase JAK STAT NO Synthase IKK Cytochrome P450
Desmethoxyyangonin (Standard) is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin (Standard) is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin (Standard) exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin (Standard) induces CYP3A23 expression and leads to skeletal muscle relaxation .

HY-167884

PF-1367550	Alkaloids Aristolochia debilis Sieb. et Zucc. Plants Aristolochiaceae Source Classification	JAK
PF-1367550 is a pan-JAK inhibitor. PF-1367550 can decrease the levels of release of CXCL9, CXCL10 and CXCL11 from primary airway epithelial cells .

HY-N0781R

Linderalactone (Standard)	Terpenoids Sesquiterpenes Plants Lauraceae Lindera aggregata (Sims) Kosterm. Source Classification	Reference Standards Apoptosis
Linderalactone (Standard) is the analytical standard of Linderalactone. This product is intended for research and analytical applications. Linderalactone is an important sesquiterpene lactone isolated from Lindera aggregata. Linderalactone inhibits cancer growth by modulating the expression of apoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lung cancer A-549 cells with an IC₅₀ of 15 μM .

HY-N0484R

Liensinine (Standard)	Alkaloids Structural Classification other families Phenols Polyphenols Plants Alkaloid Dimers Source Classification	Reference Standards Reactive Oxygen Species (ROS) Autophagy Apoptosis VEGFR JAK Amyloid-β p38 MAPK HIF/HIF Prolyl-Hydroxylase STAT PI3K JNK Akt
Liensinine (Standard) is the analytical standard of Liensinine (HY-N0484). This product is intended for research and analytical applications. Liensinine is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine exerts anti-tumor effects through ROS-mediated inhibition of the *JAK2/STAT3* signaling pathway. Liensinine can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .

HY-N8098

Pulchinenoside E2	Triterpenes Structural Classification Classification of Application Fields Terpenoids Ranunculaceae Plants Disease Research Fields Pulsatilla chinensis (Bunge) Regel Source Classification Cancer	STAT Autophagy JAK
Pulchinenoside E2 is a triterpenoid saponin. Pulchinenoside E2 inhibits the phosphorylation of STAT3 and *JAK2, blocks the nuclear translocation and transcriptional activity of STAT3, and suppresses STAT3-dependent mitochondrial oxidative phosphorylation. Pulchinenoside E2 inhibits* invasion, migration and autophagy of triple-negative breast cancer cells. Pulchinenoside E2 can be used in research related to triple-negative breast cancer .

Cat. No.	Product Name	Chemical Structure

HY-117287

Deucravacitinib

Maximum Cited Publications

33 Publications Verification

Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

HY-50856S

Deuruxolitinib
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active *JAK1* and *JAK2* inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata .

HY-131968

BMS-986202

1 Publications Verification

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-15315S

Baricitinib-d5
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-153701S

Envudeucitinibum

Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

HY-16561S

Resveratrol-d4

Resveratrol-d₄ is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-169326S

JAK2-IN-11
JAK2-IN-11 (Example 6) is a *JAK2* kinase inhibitor with IC₅₀ ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-161684

JAK2-IN-10
JAK2-IN-10 is a selective JAK2 V617F inhibitor with an IC₅₀ value of ≤10 nM . JAK2-IN-10 can be used for the research of myeloproliferative neoplasms and other related diseases .

HY-40354S

Tofacitinib-13C3
Tofacitinib- ¹³C₃ is the ¹³C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

HY-W062703S

(Rac)-Ruxolitinib-d9
(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor .

HY-W727879

Upadacitinib-15N,d2

1 Publications Verification

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-19569S1

Upadacitinib-d5

Upadacitinib-d₅ (ABT-494-d₅) is the deuterium labeled Upadacitinib (HY-19569). Upadacitinib (ABT-494) is a potent, orally active and selective JAK1 inhibitor (IC₅₀ = 43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-16379S

Pacritinib-d4
Pacritinib-d₈ (SB1518-d₈) is the deuterium labeled Pacritinib (HY-16379). Pacritinib (SB1518) is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM).

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-40354AS

Tofacitinib-d3 citrate
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-40354S1

Tofacitinib-13C3,15N
Tofacitinib- ¹³C₃, ¹⁵N (Tasocitinib- ¹³C₃, ¹⁵N) is ¹³C and ¹⁵N labeled Tofacitinib. Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-144031S

Tyk2-IN-8
Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC₅₀ of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC₅₀ of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease .

HY-10961S8

Momelotinib-d4 dihydrochloride hydrate
Momelotinib-d₄ (CYT387-d₄) dihydrochloride hydrate is a deuterium labeled Momelotinib (HY-10961). Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC₅₀s of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3 .

HY-50856S2

Ruxolitinib-d9
Ruxolitinib-d₉ (INCB18424-d₉) is deuterium labeled Ruxolitinib. Ruxolitinib (INCB18424) is an orally active and selective *JAK1/2* inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .

HY-15315S1

Baricitinib-d3
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-16561S1

Resveratrol-13C6

Resveratrol- ¹³C₆ is the ¹³C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-10409S

Fedratinib-d9

Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-40354S3

Tofacitinib-13C
Tofacitinib- ¹³C (Tasocitinib- ¹³C) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-40354S5

Tofacitinib-d3
Tofacitinib-d₃ (Tasocitinib-d₃) is deuterium labeled Tofacitinib. Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-103018S

Gusacitinib-d4

Gusacitinib-d₄ (ASN-002-d₄) is the deuterium labeled Gusacitinib (HY-103018). Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .

HY-40354S2

Tofacitinib-13C,d3
Tofacitinib- ¹³C,d₃ (Tasocitinib- ¹³C,d₃) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-169984S

Tyk2-IN-22-d3
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits Tyk2, *JAK1, and JAK3* with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation .

HY-145588S

Povorcitinib-d6
Povorcitinib-d₆ (INCB54707-d₆) is the deuterium labeled Povorcitinib (HY-145588). Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) .

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16561G

Resveratrol trans-Resveratrol; SRT501	DNA/RNA Synthesis IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Keap1-Nrf2	Infection Inflammation/Immunology Cancer
Resveratrol (GMP) is Resveratrol (HY-16561) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, *JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-15244G

Alpelisib	PI3K Apoptosis	Cancer
Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and *JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits* the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks